MacroChem deal

MCHM and Rhône-Poulenc Rorer's Dermik Laboratories Inc. subsidiary will develop a drug for psoriasis that incorporates MCHM's soft enhancement of percutaneous absorption (SEPA) technology with an undisclosed Dermik product.

MCHM said the Dermik drug is already on the market for another indication. SEPA may allow Dermik to use lower doses of the medication but achieve clinically significant concentrations in the target tissues. ...